Rimonabant CAS NO.168273-06-1

Description:

It is said that Rimonabant in a third of the users to reduce the body fat by 10%. In addition, it is reported that if the patient remains in Rimonabant, then these users in the next two years did not recover more than one kilogram. It is recommended that Rimonabant be used for obese subjects with a body mass index of 30 or more and is the most successful combination with exercise and proper diet. Do not recommend those who just want to lose a few pounds of people. Cessation treatment is valuable in the treatment of smoking cessation, the initial results are positive.

Rimonabant is an anorexia anti-obesity drug produced and sold by Sanofi-Anantes. It is the inverse agonist of cannabinoid receptor CB1. The main way is to reduce appetite. Rimonabant is the first selective CB1 receptor blocker approved for use anywhere in the world. Rimonabant was approved in 38 countries, including E.U., Mexico and Brazil. It was refused approval for use in the United States. This decision was made after the US Advisory Committee recommended that the drug was not approved because it could increase suicide thinking and depression.

Rimonabant works by blocking the binding of endogenous cannabinoids to neuronal CB1 receptors. Activation of these receptors through endogenous cannabinoids such as anorthidine increases the appetite of an individual. By blocking the activation of the receptor, an appetite suppressant may occur.

Applications:

Rimonabant (Acomplia) plays an important role in the regulation of glucose and lipid (or fat) metabolism, including adipose tissue, liver, gastrointestinal tract and muscle, by selectively blocking CB1 receptors found in the brain and peripheral organs.

Acomplia closes the same brain circuit, causing people to go hungry when smoking.

CB1 receptor blockade with Acomplia is a decrease in the overactivity of the endocannabinoid system (EC system) .3 The EC system is a recently described biological system that includes receptors such as CB1 receptors and Has been shown to play an important role in CB1 receptor blockade to regulate body weight and control energy balance, as well as glucose and lipid (or fat) metabolism.

What is Rimonabant used for

1) Rimonabant (Acomplia) is being used to supplement diets and exercise to treat obese or overweight patients with type 2 diabetes and abnormal levels of blood in the blood.

2) Sanofi believes that Acomplia can also prevent the risk of cardiovascular disease.

Waist large (male 102 cm, female 88 cm) patients are said to take the most drugs.

3) quit smoking

It may also be found that Rimonabant is effective in helping some smokers quit smoking. First, use Limone to help quit smoking; second, help prevent smokers from gaining weight.

Dosage:

It is expected that the daily dose of tamonafan is 20 mg once daily before breakfast. Elderly recommends that no dose adjustment be made, but should be used with care in patients over 75 years of age.

Although Limofanam can be used in patients with mild liver injury, but the proposed moderate impairment in patients with caution. For patients with severe liver damage, medication is not recommended.

For patients with mild to moderate renal impairment, Rimonabant can be used with care, but patients with severe renal impairment are not recommended.

There is no data to support the use of Limone in the pediatric population.

Patients who should not be allergic to any of the compounds found in the pharmaceutical or tablet formulations should not be given Rimonabant.

The drug is contraindicated in lactating women and is not recommended for pregnant women.